MediWound Ltd. Ordinary Shares MDWD
i
Market datapartial · fetched 2026-11-12T00:56:49.750Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.278250998Z
FundamentalsAlpha Vantage · unavailable
MediWound Ltd. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 10.08 | 363.6% | 35.6% | |||
| 25Δ | 11.27 | 290.3% | 27.0% | |||
| 30Δ | 12.17 | 241.2% | 20.7% | |||
| 35Δ | 18.29 | 292.0% | 40.8% | 12.85 | 207.7% | 16.2% |
| 40Δ | 16.39 | 237.8% | 27.1% | 13.33 | 180.5% | 12.8% |
| 45Δ | 13.76 | 155.2% | 9.8% | |||
| 50Δ | 14.13 | 137.5% | 7.5% | |||
| 55Δ | 14.43 | 129.2% | 6.2% | |||
| 60Δ | 14.74 | 120.9% | 4.9% | |||
| 65Δ | 12.97 | 160.6% | 7.0% | 15.03 | 112.8% | 3.7% |
| 70Δ | 12.65 | 147.7% | 5.4% | 15.30 | 106.4% | 3.0% |
| 75Δ | 12.33 | 134.8% | 3.9% | 15.56 | 99.9% | 2.2% |
| 80Δ | 12.01 | 121.9% | 2.4% | 15.82 | 93.5% | 1.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.08
- IV
- 363.6%
- B/E move
- 35.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.27
- IV
- 290.3%
- B/E move
- 27.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.17
- IV
- 241.2%
- B/E move
- 20.7%
35Δ
- Pseudo strike
- 18.29
- IV
- 292.0%
- B/E move
- 40.8%
- Pseudo strike
- 12.85
- IV
- 207.7%
- B/E move
- 16.2%
40Δ
- Pseudo strike
- 16.39
- IV
- 237.8%
- B/E move
- 27.1%
- Pseudo strike
- 13.33
- IV
- 180.5%
- B/E move
- 12.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.76
- IV
- 155.2%
- B/E move
- 9.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.13
- IV
- 137.5%
- B/E move
- 7.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.43
- IV
- 129.2%
- B/E move
- 6.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.74
- IV
- 120.9%
- B/E move
- 4.9%
65Δ
- Pseudo strike
- 12.97
- IV
- 160.6%
- B/E move
- 7.0%
- Pseudo strike
- 15.03
- IV
- 112.8%
- B/E move
- 3.7%
70Δ
- Pseudo strike
- 12.65
- IV
- 147.7%
- B/E move
- 5.4%
- Pseudo strike
- 15.30
- IV
- 106.4%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- 12.33
- IV
- 134.8%
- B/E move
- 3.9%
- Pseudo strike
- 15.56
- IV
- 99.9%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 12.01
- IV
- 121.9%
- B/E move
- 2.4%
- Pseudo strike
- 15.82
- IV
- 93.5%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 65.82% | |
| 74.56% | |
| 76.04% | |
| 74.17% | |
| 78.18% | |
| 66.64% | |
| 76.04% | |
| 66.33% | |
| 64.55% | |
| 72.46% |
Biotechnology
MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
More →MESO
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
More →MGNX
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville,…
More →MGTX
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New…
More →MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver…
More →MIST
Description unavailable
More →